Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Uchida, Naoyuki  [Clear All Filters]
2022
Tamaki M, Kameda K, Kimura S-I, Harada N, Uchida N, Doki N, Tanaka M, Ikegame K, Sawa M, Katayama Y, et al. Deletion of Y-chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors. Blood Adv. 2022.
Kimura M, Asano-Mori Y, Sakoh T, Abe M, Ueno K, Hoshino Y, Nakamura S, Umeyama T, Yamagoe S, Miyazaki Y, et al. Factors associated with breakthrough fungemia caused by , , or species when the breakthrough fungemia developed in patients with hematological disorders. Antimicrob Agents Chemother. 2022:AAC0208121.
Okada Y, Nakasone H, Konuma T, Uchida N, Tanaka M, Sugio Y, Aotsuka N, Nishijima A, Katsuoka Y, Ara T, et al. Ideal body weight is useful for predicting neutrophil engraftment and platelet recovery for overweight and obese recipients in single-unit cord blood transplantation. Transplant Cell Ther. 2022.
Itonaga H, Kida M, Hamamura A, Uchida N, Ozawa Y, Fukuda T, Ueda Y, Kataoka K, Katayama Y, Ota S, et al. Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis. Hematol Oncol. 2022.
Kimura S-I, Kameda K, Harada K, Saburi M, Okinaka K, Shinohara A, Uchida N, Nishijima A, Ozawa Y, Tanaka M, et al. Risk and predictive factors for candidemia after allogeneic hematopoietic cell transplantation: JSTCT Transplant Complications Working Group. Transplant Cell Ther. 2022.
2021
Yamamuro R, Kimura M, Asano-Mori Y, Abe M, Nakamura S, Umeyama T, Yamagoe S, Miyazaki Y, Ogura S, Sakoh T, et al. Clinical and microbiological characteristics of proven invasive aspergillosis due to rare/cryptic species in allogeneic hematopoietic stem cell transplant recipients. Antimicrob Agents Chemother. 2021:AAC0163021.
Kanda Y, Inoue M, Uchida N, Onishi Y, Kamata R, Kotaki M, Kobayashi R, Tanaka J, Fukuda T, Fujii N, et al. Cryopreservation of unrelated hematopoietic stem cells from a blood and marrow donor bank during the COVID-19 pandemic. A nationwide survey by the Japan Marrow Donor Program. Transplant Cell Ther. 2021.
Sakurai M, Mori T, Kato K, Kanaya M, Mizuno S, Shiratori S, Wakayama T, Uchida N, Kobayashi H, Kubo K, et al. Outcome of allogeneic hematopoietic stem cell transplantation for follicular lymphoma relapsing after autologous transplantation: analysis of the Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2021.
Konuma T, Aoki J, Ozawa Y, Uchida N, Kobayashi T, Onizuka M, Katayama Y, Ohta T, Nakano N, Ota S, et al. Pre-transplant red blood cell and platelet transfusion burden in de novo myelodysplastic syndrome undergoing allogeneic transplantation: Pre-transplant red blood cell and platelet transfusion burden in de novo MDS after allogeneic transplantation. Transplant Cell Ther. 2021.
2020
Harada K, Fuji S, Seo S, Uchida N, Kawakita T, Yano S, Ozawa Y, Yoshioka S, Onishi Y, Noguchi Y, et al. Comparison of immunosuppressant regimens in salvage cord blood transplantation for graft failure after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020.
Akahoshi Y, Kimura S-I, Inamoto Y, Seo S, Muranushi H, Shimizu H, Ozawa Y, Tanaka M, Uchida N, Kanda Y, et al. Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality. Clin Infect Dis. 2020.
Yokoyama H, Takenaka K, Nishida T, Seo S, Shinohara A, Uchida N, Tanaka M, Takahashi S, Onizuka M, Kozai Y, et al. Favorable effect of cytomegalovirus reactivation on outcomes in cord blood transplantation and its differences among disease risk or types. Biol Blood Marrow Transplant. 2020.
Kaito S, Nakajima Y, Hara K, Toya T, Nishida T, Uchida N, Mukae J, Fukuda T, Ozawa Y, Tanaka M, et al. Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation. Blood Adv. 2020;4(6):1051-1061.
Akahoshi Y, Igarashi A, Fukuda T, Uchida N, Tanaka M, Ozawa Y, Kanda Y, Onizuka M, Ichinohe T, Tanaka J, et al. Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia. Br J Haematol. 2020.
Hirakawa Y, Fujimoto T, Ishida S, Uchida N, Sawa S, Kiyosue T, Ishizaki K, Nishihama R, Kohchi T, Bowman JL. Induction of Multichotomous Branching by CLAVATA Peptide in Marchantia polymorpha. Curr Biol. 2020.
Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Ogata M, Sugio Y, Fukuda T, Uchida N, Ikegame K, Matsuoka K-I, et al. Low incidence of post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab. Hematol Oncol. 2020.
Takenaka K, Onishi Y, Mori T, Hirakawa T, Tada Y, Uchida N, Kobayashi T, Kanda Y, Ozawa Y, Ota S, et al. Negative Impact of Cytomegalovirus Reactivation on Survival in Adult Patients with Aplastic Anemia After an Allogeneic Hematopoietic Stem Cell Transplantation: A Report from Transplantation-Related Complication and Adult Aplastic Anemia Working Groups of . Biol Blood Marrow Transplant. 2020.
Kida M, Usuki K, Uchida N, Fukuda T, Katayama Y, Kondo T, Eto T, Matsuoka K-I, Matsuhashi Y, Ota S, et al. Outcome and Risk Factors for Therapy-Related Myeloid Neoplasms Treated with Allogeneic Stem Cell Transplantation in Japan. Biol Blood Marrow Transplant. 2020.
Kurosawa S, Shimomura Y, Tachibana T, Ishiyama K, Ota S, Kobayashi T, Uchida N, Fukushima K, Ashida T, Matsuoka K-I, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic/myeloproliferative neoplasms-unclassifiable: a retrospective nationwide study of the Japan Society for Hematopoietic Cell Transplantation: Allo-HSCT for patient. Biol Blood Marrow Transplant. 2020.
Yuasa M, Yamamoto H, Mitsuki T, Kageyama K, Kaji D, Taya Y, Nishida A, Ishiwata K, Takagi S, Yamamoto G, et al. Prognostic impact of cytogenetic evolution on the outcome of allogeneic stem cell transplantation in patients with acute myeloid leukemia in non-remission: A single institute analysis of 212 recipients. Biol Blood Marrow Transplant. 2020.
Akahoshi Y, Nishiwaki S, Arai Y, Harada K, Najima Y, Kanda Y, Shono K, Ota S, Fukuda T, Uchida N, et al. Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia W. Bone Marrow Transplant. 2020.
2019
Kondo E, Shimizu-Koresawa R, Chihara D, Mizuta S, Izutsu K, Ikegame K, Uchida N, Fukuda T, Ichinohe T, Atsuta Y, et al. Allogeneic haematopoietic stem cell transplantation for primary mediastinal large B-cell lymphoma patients relapsing after high dose chemotherapy with autologous stem cell transplantation: data from the Japan Society for Haematopoietic Cell Transplantatio. Br J Haematol. 2019.
Ikeda T, Mori K, Kawamura K, Mori T, Hagiwara S, Ueda Y, Kahata K, Uchida N, Tsukada N, Murakami S, et al. Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation. Hematol Oncol. 2019.
Murata M, Takenaka K, Uchida N, Ozawa Y, Ohashi K, Kim S-W, Ikegame K, Kanda Y, Kobayashi H, Ishikawa J, et al. Comparison of outcomes of allogeneic transplantation for primary myelofibrosis among hematopoietic stem cell source groups. Biol Blood Marrow Transplant. 2019.
Konuma T, Kondo T, Mizuno S, Doki N, Aoki J, Fukuda T, Tanaka M, Sawa M, Katayama Y, Uchida N, et al. Conditioning intensity for allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients with poor-prognosis cytogenetics in first complete remission. Biol Blood Marrow Transplant. 2019.

Pages